Biotech at Discount Prices: Buy This High-Growth Small Cap Now

The broader biotech segment is still off its recent highs. And this “Strong Bullish” stock sells for a discount today. [Turn Your Images On] Green Zone Ratings [Biotech at Discount Prices: Buy This High-Growth Small Cap Now]( [Turn Your Images On] [Matt Clark, Research Analyst]( COVID-19 pushed biotechnology companies into overdrive in search of a vaccine. From big vaccine producers to smaller companies that provide DNA to test those vaccines, the entire industry shifted into high gear. And underlying stocks followed suit. Investors piled into biotech stocks right after the March 2020 COVID-19 crash. You can see that in the chart of the S&P Biotechnology Select Industry Index below. But investors recently moved out of techy growth stocks and into value-based stocks. This recent sell-off of biotech stocks is cyclical and not likely to last. The broader Nasdaq Composite already regained most of its losses. It even hit new record highs last month! So now is the perfect time to buy into high-growth biotech stocks at a reduced price — before they boom higher again! It’s just a matter of finding the right company within one of the hottest — yet unknown — sectors of the market. That’s where Adam O’Dell’s Green Zone Ratings system comes in. I used it to find a biotech stock with incredible growth potential, and a price-to-earnings ratio in the single digits — almost 50 points lower than the industry average! [Click here to see why now is the perfect time to buy this “Strong Bullish” biotech stock.]( Suggested Stories: [3 Major Crypto Breakthroughs: Buy BTC or ETH?]( [Will Biden’s Tax Hike Scare Big Money Out of the Markets?]( --------------------------------------------------------------- FROM OUR PARTNERS [No. 1 Stock for the Green Energy Boom]( America’s $51 trillion green boom will be of unheard magnitude. Only it’s not from anything Biden is doing. Or from any big corporation. Instead, one pioneering company is at the forefront. You won’t believe what it’s battery tech can do. It’s 25X more powerful than a Tesla EV. [Click here for the full story.]( --------------------------------------------------------------- Chart of the Day [Turn Your Images On] [Michael Carr, CMT]( [Who’s to Blame for Automakers’ Chip Shortage?]( Last week, General Motors reported strong earnings. The company announced a net income of $3 billion, about 10 times more than it made in the same quarter a year ago. GM could have had a better quarter, but “revenue and vehicle sales fell slightly from a year ago because the global chip shortage and plant closings limited supply of vehicles. International sales also dropped.” That shortage is expected to cost the company up to $2 billion in earnings this year. While some analysts believe the chip shortage is because electronics makers are buying more chips, that’s only part of the story. [The chart below tells another. Click here to find out why.]( Suggested Stories: [$1.5T in Excess Savings Burns a Hole in American Pockets]( [Global K-Shaped Recovery Threatens the U.S.]( --------------------------------------------------------------- FROM OUR PARTNERS [This Could Be One of the Greatest Financial Opportunities in the History of the Markets.]( If you’re interested in finding high-performance investments that could return annual gains of 50%, 100% and even 200% (or more), keep reading. Warren Buffett, Bill Gates, Richard Branson, Jeff Bezos, and Mark Zuckerberg are investing BILLIONS in this opportunity… [Discover how you can profit along with these billionaires]( --------------------------------------------------------------- 1998: A French mint produced the first coins of Europe's single currency, known as the euro. Privacy Policy The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482. To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or [whitelist]( within your spam settings. For customer service questions or issues, please contact us for assistance. The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: [( Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets expressly forbids its writers from having a financial interest in their own securities or commodities recommendations to readers. Such recommendations may be traded, however, by other editors, Money & Markets, its affiliated entities, employees, and agents, but only after waiting 24 hours after an internet broadcast or 72 hours after a publication only circulated through the mail. (c) 2021 Money & Markets. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471) Remove your email from this list: [Click here to Unsubscribe](